FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212877247> ?p ?o ?g. }

• W3212877247 endingPage "1246" @default.
• W3212877247 startingPage "1246" @default.
• W3212877247 abstract "Abstract Background: Venetoclax-based combinations were recently approved to treat patients (pts) with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Limited prospective 'real-world' data is available on treatment patterns of venetoclax-based therapy in routine clinical practice. We investigated patterns of patient selection, efficacy, toxicity, patient related outcome and post-remission management in a nationwide multicenter prospective observational trial. Methods: Newly diagnosed pts with AML were enrolled at the time of venetoclax-based therapy initiation from 10 medical centers in Israel. Demographic, clinical and patient-related baseline characteristics were documented. Treatment patterns, safety and efficacy outcomes are reported. Results: Between August 12, 2019, and June 17, 2021(data cut) ,127 AML pts were enrolled to receive venetoclax based therapy. Baseline patient and disease characteristics are reported in Table 1. The main reasons for physician's choice of venetoclax-based therapy were age ≥75, comorbidities and ECOG ≥2 (patient related factors) in 76% of cases and adverse disease biology predicting poor response to intensive chemotherapy (disease related factors) in 24% of cases. Most pts started therapy in an inpatient setting, 82 (64.6%) with a median hospitalization duration of 14 days, while 44 pts (34.6%) started therapy as out pts. Pts received a median of 3.8 cycles of therapy (range 1-21). Most pts (97%) received venetoclax in combination with hypomethylating agents. The full dose of 400mg QD after a median ramp-up duration of 3 days was achieved in 88% of the pts. Dose interruptions and dose modifications during follow-up occurred in 59 (46%) and 30 (24%) of pts, respectively. To allow for adequate follow up for response assessment, efficacy analysis was limited to pts enrolled prior to December 31, 2020, and included 108 pts with a median follow-up of 8 months (range 1-20). As of data cut, 93 pts completed cycle 1 of therapy, 66 pts completed cycle 3 and 39 pts completed cycle 6. 29 pts (27%) are still active on treatment. Best composite complete remission [CCR = complete remission (CR) plus CR with incomplete count recovery (CRi)] was achieved in 62 (57%) pts. CCR rates were assessed in different pre-defined subgroups. Best CCR in pts selected for therapy based on disease-related and patient-related factors were 70% and 54% respectively. Best CCR in pts with AML arising from MPN and pts with other AML were 45% and 58% respectively. Estimated median overall survival (OS) of all pts was 9.6 months (range 7.4-10.6) (Figure 1). Achieving CCR was associated with a superior probability for survival. Estimated median OS was 13.6 months (range 10.6 - not reached) in pts achieving CCR and 4.2 months (range 1.2-10.3) in non-CCR (p&lt;.0001). Of responding pts (CR/CRi, partial remission (PR), morphologic leukemia free state (MLFS), 27 (37%) progressed. Estimated median time to progression was 9.2 months (6.7-NR). Allogeneic transplantation following venetoclax based treatment was offered to 16 (26%) pts with a median age of 71 years (range 43-77). Last documented response prior to transplant was CR in 5 (32%) pts, CRi 9 (56%), MLFS 1 (6%) and PR in 1 (6%) patient. Among grade ≥3 AEs were febrile neutropenia in 28% and infections in 21% of pts. Clinical and laboratory tumor lysis syndrome (TLS) was documented in 2 and 4 pts, respectively. Antifungal prophylaxis was administered in 20% of pts and granulocyte colony-stimulating factor (GCSF) support was used in 17% of pts in response. Early death rate at 30 and 60 days were 7% and 13%, respectively. Conclusion: This prospective real-world analysis reveals unique patterns of patient selection and venetoclax treatment utilization in a medical system with wide access for this indication. Venetoclax-based therapies are effective and associated with manageable toxicity, including in AML patient populations that were excluded from previous registration trials with comparable CCR and early death rates. Factors associated with patient selection in the 'real-world' setting and immature follow up data most probably led to a shorter estimated median OS in this analysis as compared to controlled trials. The REVIVE study continues to expand and is expected to provide additional insights on treatment patterns, management as well as clinical and patient related outcomes. Figure 1 Figure 1. Disclosures Wolach: Janssen: Consultancy; Novartis: Consultancy; Amgen: Research Funding; Astellas: Consultancy; Abbvie: Consultancy, Honoraria, Research Funding; Neopharm: Consultancy. Levi: AbbVie: Consultancy, Research Funding. Lavie: AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Fees for lectures; BMS: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Other: Fees for lectures; Roche: Other: Fees for lectures; Novartis: Other: Fees for lectures. Tavor: AbbVie: Consultancy. Hellmann: AbbVie: Consultancy. Tadmor: Janssen: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Zuckerman: Gilead Sciences: Honoraria, Speakers Bureau; Novartis: Honoraria; Janssen: Honoraria; Cellect Biotechnology: Honoraria; BioSight Ltd: Honoraria; AbbVie: Honoraria; Orgenesis Inc.: Honoraria. Stemer: AbbVie: Consultancy. Berelovich: AbbVie: Current Employment, Current equity holder in publicly-traded company. Ofek: AbbVie: Current Employment, Current equity holder in publicly-traded company. Frankel: AbbVie: Current Employment, Current equity holder in publicly-traded company. Grunspan: AbbVie: Current Employment, Other: May hold equity. Ofran: Medison Israel: Consultancy; Pfizer: Consultancy; Astellas: Consultancy; AbbVie: Consultancy; Janssen: Consultancy. Moshe: Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; Astellas: Membership on an entity's Board of Directors or advisory committees, Other: Lectures; AbbVie: Membership on an entity's Board of Directors or advisory committees, Other: Lectures." @default.
• W3212877247 created "2021-11-22" @default.
• W3212877247 creator A5001922074 @default.
• W3212877247 creator A5009969844 @default.
• W3212877247 creator A5011180142 @default.
• W3212877247 creator A5019626882 @default.
• W3212877247 creator A5025358969 @default.
• W3212877247 creator A5029025432 @default.
• W3212877247 creator A5037018787 @default.
• W3212877247 creator A5039225281 @default.
• W3212877247 creator A5039876592 @default.
• W3212877247 creator A5041902596 @default.
• W3212877247 creator A5042528560 @default.
• W3212877247 creator A5057223012 @default.
• W3212877247 creator A5077836212 @default.
• W3212877247 creator A5081917477 @default.
• W3212877247 creator A5086382795 @default.
• W3212877247 date "2021-11-05" @default.
• W3212877247 modified "2023-10-01" @default.
• W3212877247 title "Real World Prospective Observational Multicenter Trial of Venetoclax-Based Therapy for Patients with AML Reveals Unique Patterns of Patient Selection and Treatment Utilization - Revive Study" @default.
• W3212877247 doi "https://doi.org/10.1182/blood-2021-147245" @default.
• W3212877247 hasPublicationYear "2021" @default.
• W3212877247 type Work @default.
• W3212877247 sameAs 3212877247 @default.
• W3212877247 citedByCount "0" @default.
• W3212877247 crossrefType "journal-article" @default.
• W3212877247 hasAuthorship W3212877247A5001922074 @default.
• W3212877247 hasAuthorship W3212877247A5009969844 @default.
• W3212877247 hasAuthorship W3212877247A5011180142 @default.
• W3212877247 hasAuthorship W3212877247A5019626882 @default.
• W3212877247 hasAuthorship W3212877247A5025358969 @default.
• W3212877247 hasAuthorship W3212877247A5029025432 @default.
• W3212877247 hasAuthorship W3212877247A5037018787 @default.
• W3212877247 hasAuthorship W3212877247A5039225281 @default.
• W3212877247 hasAuthorship W3212877247A5039876592 @default.
• W3212877247 hasAuthorship W3212877247A5041902596 @default.
• W3212877247 hasAuthorship W3212877247A5042528560 @default.
• W3212877247 hasAuthorship W3212877247A5057223012 @default.
• W3212877247 hasAuthorship W3212877247A5077836212 @default.
• W3212877247 hasAuthorship W3212877247A5081917477 @default.
• W3212877247 hasAuthorship W3212877247A5086382795 @default.
• W3212877247 hasConcept C126322002 @default.
• W3212877247 hasConcept C143998085 @default.
• W3212877247 hasConcept C187212893 @default.
• W3212877247 hasConcept C197934379 @default.
• W3212877247 hasConcept C23131810 @default.
• W3212877247 hasConcept C2776694085 @default.
• W3212877247 hasConcept C2777938653 @default.
• W3212877247 hasConcept C2778336483 @default.
• W3212877247 hasConcept C2778461978 @default.
• W3212877247 hasConcept C2779675984 @default.
• W3212877247 hasConcept C2781413609 @default.
• W3212877247 hasConcept C71924100 @default.
• W3212877247 hasConceptScore W3212877247C126322002 @default.
• W3212877247 hasConceptScore W3212877247C143998085 @default.
• W3212877247 hasConceptScore W3212877247C187212893 @default.
• W3212877247 hasConceptScore W3212877247C197934379 @default.
• W3212877247 hasConceptScore W3212877247C23131810 @default.
• W3212877247 hasConceptScore W3212877247C2776694085 @default.
• W3212877247 hasConceptScore W3212877247C2777938653 @default.
• W3212877247 hasConceptScore W3212877247C2778336483 @default.
• W3212877247 hasConceptScore W3212877247C2778461978 @default.
• W3212877247 hasConceptScore W3212877247C2779675984 @default.
• W3212877247 hasConceptScore W3212877247C2781413609 @default.
• W3212877247 hasConceptScore W3212877247C71924100 @default.
• W3212877247 hasIssue "Supplement 1" @default.
• W3212877247 hasLocation W32128772471 @default.
• W3212877247 hasOpenAccess W3212877247 @default.
• W3212877247 hasPrimaryLocation W32128772471 @default.
• W3212877247 hasRelatedWork W1507921223 @default.
• W3212877247 hasRelatedWork W1984282923 @default.
• W3212877247 hasRelatedWork W2022084568 @default.
• W3212877247 hasRelatedWork W2373226427 @default.
• W3212877247 hasRelatedWork W2387456186 @default.
• W3212877247 hasRelatedWork W2388730008 @default.
• W3212877247 hasRelatedWork W2924174799 @default.
• W3212877247 hasRelatedWork W3215662100 @default.
• W3212877247 hasRelatedWork W4296769090 @default.
• W3212877247 hasRelatedWork W757206253 @default.
• W3212877247 hasVolume "138" @default.
• W3212877247 isParatext "false" @default.
• W3212877247 isRetracted "false" @default.
• W3212877247 magId "3212877247" @default.
• W3212877247 workType "article" @default.